ZYME
Zymeworks Inc.Company Information
- Company Name
- Zymeworks Inc.
- CIK
- CIK0001937653
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- ZYME: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ZYME
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-05-19
- Last sale
- 2026-01-12
- Shares purchased (TTM)
- 983,453
- Shares sold (TTM)
- 187,933
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 68,320,578
- Shares outstanding
- 72,993,313
- Ownership
- 93.60%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- 22.22%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 179 | 244 | 41 | 65 | 98 | 76 | 66 | 122 | 71 | 115 | 158 | 94 | ||||||
| Debt Securities Available For Sale Excluding Accrued Interest Current | 91 | 120 | 188 | 187 | 183 | 189 | 160 | 175 | 259 | 230 | 217 | - | ||||||
| Short Term Investments | - | - | - | - | - | - | - | - | - | - | 217 | 201 | ||||||
| Accounts Receivable Net Current | 6 | 5 | 5 | 29 | 3 | 25 | 56 | 24 | 32 | 31 | 19 | 67 | ||||||
| Prepaid Expense And Other Assets Current | 22 | 16 | 15 | 10 | 12 | 17 | 19 | 23 | 21 | 18 | 19 | 12 | ||||||
| Assets Current | 298 | 386 | 249 | 292 | 296 | 306 | 300 | 344 | 383 | 394 | 413 | 375 | ||||||
| Debt Securities Available For Sale Excluding Accrued Interest Noncurrent | 52 | 39 | 42 | 47 | 52 | 56 | 98 | 78 | 66 | 75 | 82 | - | ||||||
| Prepaid Expense And Other Assets Noncurrent | 2 | 7 | 7 | 7 | 9 | 9 | 9 | 7 | 7 | 8 | 8 | - | ||||||
| Long Term Investments | - | - | - | - | - | - | - | - | - | - | 82 | 96 | ||||||
| Prepaid Expense Noncurrent | - | - | - | - | - | - | - | - | - | - | 7 | 8 | ||||||
| Deferred Income Tax Assets Net | 4 | 5 | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 4 | 4 | 1 | ||||||
| Property Plant And Equipment Net | 14 | 15 | 16 | 16 | 16 | 17 | 18 | 18 | 18 | 19 | 20 | 21 | ||||||
| Operating Lease Right Of Use Asset | 13 | 14 | 16 | 17 | 16 | 17 | 17 | 17 | 17 | 17 | 18 | 18 | ||||||
| Finite Lived Intangible Assets Net | 1 | 1 | 1 | 1 | 2 | 3 | 5 | 6 | 7 | 7 | 8 | 8 | ||||||
| Indefinite Lived Intangible Assets Excluding Goodwill | - | - | - | - | - | - | 0 | - | 0 | 18 | 18 | 18 | ||||||
| Goodwill | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | ||||||
| Assets | 397 | 478 | 347 | 397 | 408 | 426 | 463 | 487 | 516 | 554 | 581 | 556 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 27 | 30 | 36 | 34 | 31 | 38 | 60 | 52 | 44 | 47 | 46 | 68 | ||||||
| Accrued Income Taxes Current | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 1 | ||||||
| Operating Lease Liability Current | 3 | 3 | 3 | 3 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | ||||||
| Derivative Fair Value Of Derivative Liability | - | - | - | - | - | - | - | - | - | - | 1 | 0 | ||||||
| Contract With Customer Liability Current | 16 | 2 | 2 | 3 | 4 | 23 | 26 | 27 | 6 | 3 | 4 | 0 | ||||||
| Liabilities Current | 47 | 36 | 42 | 42 | 39 | 65 | 88 | 84 | 55 | 57 | 56 | 73 | ||||||
| Operating Lease Liability Noncurrent | 13 | 14 | 15 | 16 | 15 | 15 | 16 | 17 | 17 | 21 | 22 | 22 | ||||||
| Contract With Customer Liability Noncurrent | 0 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 33 | 33 | 33 | 33 | ||||||
| Other Liabilities Noncurrent | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | ||||||
| Deferred Income Tax Liabilities Net | 4 | 4 | 6 | 5 | 5 | 5 | 5 | 3 | 3 | 3 | 3 | 2 | ||||||
| Liabilities | 317 | 315 | 78 | 77 | 74 | 101 | 124 | 120 | 109 | 116 | 116 | 132 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 1,134 | 1,129 | 1,105 | 1,093 | 1,074 | 1,022 | 1,016 | 1,014 | 1,005 | 1,003 | 997 | 932 | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 116 | 108 | 115 | 111 | 109 | 154 | 152 | 148 | 147 | 143 | 142 | 154 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -7 | -7 | -6 | -6 | -6 | -6 | -7 | -6 | -8 | -8 | -7 | -8 | ||||||
| Retained Earnings Accumulated Deficit | -1,171 | -1,074 | -953 | -886 | -851 | -853 | -830 | -798 | -747 | -709 | -677 | -663 | ||||||
| Stockholders Equity | 80 | 164 | 269 | 320 | 335 | 325 | 339 | 367 | 406 | 438 | 465 | 424 | ||||||
| Liabilities And Stockholders Equity | 397 | 478 | 347 | 397 | 408 | 426 | 463 | 487 | 516 | 554 | 581 | 556 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 900 | 900 | 900 | 900 | 900 | 900 | 900 | 900 | 900 | 900 | 900 | 900 | ||||||
| Common Stock Shares Issued | 71 | 73 | 75 | 75 | 75 | 70 | 69 | 70 | 71 | 71 | 70 | 68 | ||||||
| Shares Outstanding | 71 | 73 | 75 | 75 | 75 | 70 | 69 | 70 | 71 | 71 | 70 | 68 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialZymeworks Inc. (ZYME) — SEC Financial Statements & Analysis
Zymeworks Inc. (ZYME) is a pharmaceutical preparations company, incorporated in DE. Zymeworks Inc. trades on Nasdaq as: ZYME. Zymeworks Inc. (ZYME)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Zymeworks Inc. carries a market cap of $1.91B, a P/E ratio of -12.72x, a P/B ratio of 23.74x, a P/S ratio of 51.39x, an enterprise value of $1.73B, and an EV/EBITDA multiple of -11.38x. On profitability, it posts an operating margin of -418.99%, a net margin of -404.00%, a Return on Equity (ROE) of -72.31%, a Return on Assets (ROA) of -37.25%, and a Return on Invested Capital (ROIC) of -36.12%. Per share, it reports EPS of $-2.05, diluted EPS of $-2.05, free cash flow per share of $-1.65, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -69.78% year-over-year, net income growth of 103.59% year-over-year, and EPS growth of 110.12% year-over-year. On the balance sheet, it maintains a current ratio of 6.32x, a quick ratio of 5.86x, working capital of $251.15M, a debt-to-equity ratio of 3.94x, a debt ratio of 0.8, an interest coverage ratio of -12.44x, free cash flow of $-120.54M (TTM), and net debt of $-179.41M. Figures sourced from SEC EDGAR.
- Market Cap
- $1.91B
- P/E TTM
- -12.72x
- EPS TTM
- $-2.05
- P/B TTM
- 23.74x
- ROE TTM
- -72.31%
- ROA TTM
- -37.25%
- Debt To Equity
- 3.94x
- Free Cash Flow TTM
- $-120.54M
- Net Revenue TTM Growth 1Y
- -69.78%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Zymeworks Inc. in?
Zymeworks Inc. (ZYME) operates in the Pharmaceutical Preparations industry.
What exchange does ZYME trade on?
Zymeworks Inc. (ZYME) trades on the Nasdaq.
Where is Zymeworks Inc. incorporated?
Zymeworks Inc. is incorporated in DE.
When was Zymeworks Inc. (ZYME)'s most recent SEC filing?
Zymeworks Inc. (ZYME)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is ZYME's market cap?
Zymeworks Inc. (ZYME) has a market capitalization of $1.91B as of 2026-06-30.
What is ZYME's EPS (earnings per share)?
Zymeworks Inc. (ZYME)'s trailing twelve month EPS is $-2.05 as of 2026-06-30.
What is ZYME's ROE (return on equity)?
Zymeworks Inc. (ZYME)'s trailing twelve month Return on Equity (ROE) is -72.31% as of 2026-06-30.
What is ZYME's ROA (return on assets)?
Zymeworks Inc. (ZYME)'s trailing twelve month Return on Assets (ROA) is -37.25% as of 2026-06-30.
What is ZYME's ROIC (return on invested capital)?
Zymeworks Inc. (ZYME)'s trailing twelve month Return on Invested Capital (ROIC) is -36.12% as of 2025-12-31.
What is ZYME's EV/EBITDA?
Zymeworks Inc. (ZYME)'s trailing twelve month EV/EBITDA is -11.38x as of 2026-06-30.